Novo Nordisk A/S Class B (NOVOb)

Copenhagen
Currency in DKK
Disclaimer
1,085.8
+6.2
(+0.57%)
Closed
Trading near 52-week High
Day's Range
1,076.8
1,092.2
52 wk Range
720.4
1,092.2
Volume
1,770,124
Prev. Close
1,079.6
Open
1,081.8
Day's Range
1,076.8-1,092.2
52 wk Range
720.4-1,092.2
Volume
1,770,124
Average Volume (3m)
1,546,907
1-Year Change
42.86%
Shares Outstanding
2,249,375,003
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More

People Also Watch

17.4100
CRDI
-0.29%
166.00
ESLX
+1.31%
625.20
ASML
+0.24%
136.35
TCFP
-0.11%
11.485
IBE
+0.70%

Novo Nordisk A/S Class B News

Novo Nordisk A/S Class B Analysis

Novo Nordisk A/S Class B Company Profile

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Employees
54789
Market
Denmark